

May 19, 2020

The Manager – Listing

BSE Limited,

1st Floor, New Trading Ring

Rotunda Building, P J Towers, Dalal Street, Fort,

Mumbai 400001

The Manager – Listing

National Stock Exchange of India Ltd.

Exchange plaza, 5th Floor, Plot No.C/1, G Block

Bandra-Kurla Complex, Bandra (E),

Mumbai 400051

Dear Sir(s),

Sub: Intimation pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN

Pursuant to regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like you to inform that:

- (a) Mr. Ian John Parish (DIN: 00391534), Non-executive Director, has resigned w.e.f. close of business hours on May 18, 2020, due to change in his roles and responsibilities at AstraZeneca.
- (b) Mr. Ankush Nandra (DIN: 0008737981) has been appointed as an Additional Director (Non-Executive) at the Board meeting held on May 18, 2020.

A brief profile of Mr. Ankush Nandra is enclosed herewith.

Mr. Ankush Nandra is not related to any other director of the Company.

We request you to please take the same on record.

Thanking you,

For **AstraZeneca Pharma India Limited**

Pratap Rudra

Company Secretary & Legal Counsel

Brief Profile of Mr. Ankush Nandra

In his current role as VP Finance & CFO International AstraZeneca based in the United Kingdom, Mr. Ankush Nandra leads the commercial finance organisation across the International Region.

He joined AstraZeneca in 2015 as the European CFO before moving to his present role in 2018.

Prior to this, he was at GSK based in the UK, US and Australia for a variety of roles including CFO for the Australia & NZ business, CFO for Global R&D and leadership of the Corporate Development Group.

Before GSK, he spent time in M&A with HSBC Investment Bank following qualification as an ACA with KPMG in London.